120 related articles for article (PubMed ID: 16226477)
1. Factors useful for predicting survival of myeloma patients in everyday practice. A 10-year study of 148 patients older than 55 years.
Chombart B; Lemoussu LG; Eschard JP; Ackah-Miezan S; Novella JL; Brochot P; Pignon B; Etienne JC
Joint Bone Spine; 2005 Dec; 72(6):544-9. PubMed ID: 16226477
[TBL] [Abstract][Full Text] [Related]
2. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
Scarffe JH; Anderson H; Palmer MK; Crowther D
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1361-4. PubMed ID: 6357802
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.
Pelliniemi TT; Irjala K; Mattila K; Pulkki K; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Blood; 1995 Feb; 85(3):765-71. PubMed ID: 7530507
[TBL] [Abstract][Full Text] [Related]
5. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
Kaneko M; Kanda Y; Oshima K; Nannya Y; Suguro M; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
Ann Hematol; 2002 Jan; 81(1):33-6. PubMed ID: 11807633
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.
Facon T; Avet-Loiseau H; Guillerm G; Moreau P; Geneviève F; Zandecki M; Laï JL; Leleu X; Jouet JP; Bauters F; Harousseau JL; Bataille R; Mary JY;
Blood; 2001 Mar; 97(6):1566-71. PubMed ID: 11238092
[TBL] [Abstract][Full Text] [Related]
7. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
[TBL] [Abstract][Full Text] [Related]
8. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
9. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
Chretien ML; Hebraud B; Cances-Lauwers V; Hulin C; Marit G; Leleu X; Karlin L; Roussel M; Stoppa AM; Guilhot F; Lamy T; Garderet L; Pegourie B; Dib M; Sebban C; Lenain P; Brechignac S; Royer B; Wetterwald M; Legros L; Orsini-Piocelle F; Voillat L; Delbrel X; Caillot D; Macro M; Facon T; Attal M; Moreau P; Avet-Loiseau H; Corre J
Haematologica; 2014 Jul; 99(7):1236-8. PubMed ID: 24727820
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
11. High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study.
Bang SM; Cho EK; Suh C; Yoon SS; Seong CM; Cho KS; Kang YG; Park S; Ahn MJ; Park YS; Oh D; Kim HC; Jung CW; Kim S; Lee JH
J Korean Med Sci; 2003 Oct; 18(5):673-8. PubMed ID: 14555819
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
13. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD
Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma in elderly patients: presenting features and outcome.
Rodon P; Linassier C; Gauvain JB; Benboubker L; Goupille P; Maigre M; Luthier F; Dugay J; Lucas V; Colombat P
Eur J Haematol; 2001 Jan; 66(1):11-7. PubMed ID: 11168502
[TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
Katodritou E; Verrou E; Hadjiaggelidou C; Gastari V; Laschos K; Kontovinis L; Kapetanos D; Constantinou N; Terpos E; Zervas K
Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886
[TBL] [Abstract][Full Text] [Related]
16. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
17. Evolution of hepatosplenic plasmacytoma in a patient with multiple myeloma receiving chemotherapy.
Malhotra P; Bhat P; Mahi S; Chauhan S; Rajwanshi A; Varma S
Am J Hematol; 2005 Jan; 78(1):82-3. PubMed ID: 15609282
[No Abstract] [Full Text] [Related]
18. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
19. Increased serum levels of beta2m-free HLA class I heavy chain in multiple myeloma.
Perosa F; Luccarelli G; Prete M; Ferrone S; Dammacco F
Br J Haematol; 1999 Sep; 106(4):987-94. PubMed ID: 10520002
[TBL] [Abstract][Full Text] [Related]
20. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
